Be a Pioneer in Transforming Global Healthcare with Ablatotech At Ablatotech, we believe in a future where healing isn’t a privilege but a right accessible to all. With your help, we can make that vision a reality. By signing up for our future clinical trials, you will play a vital role in advancing life-changing medical breakthroughs that have the power to redefine global healthcare. Why Join Our Mission? Empower Innovation: Your participation drives research that unlocks the body’s natural potential to heal itself, paving the way for safer, more effective treatments. Make a Difference: Be part of solutions that bring cutting-edge healthcare to underserved populations worldwide. Shape the Future: Together, we can pioneer technologies that revolutionize medicine and transform lives on a global scale. At Ablatotech, every clinical trial is a step toward groundbreaking progress. Your willingness to be involved could lead to treatments that touch countless lives. Sign Up Today Join our growing community of visionaries. By registering for future clinical trials, you’ll be the first to know about exciting opportunities to participate in research that truly matters. Help us shape a healthier tomorrow. Together, we can revolutionize medicine—one trial at a time. Please signup below, today. Your contribution today will help change lives tomorrow. First Name Last Name Email Location Phone Year of Birth Race Select a Race Ethnicity Enter your ethnicity Gender Select a gender Condition Choose an option I agree to the terms & conditions View terms of use Sign Up Submitted! Thanks for your interest in Ablatotech clinical trials.

Terms of Use for Participation in Nygela Clinical Trials at Ablatotech Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Nygela clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Nygela clinical trial aims to evaluate the safety, effectiveness, and tolerability of Nygela, a topical, natural, steroid-free cream designed to treat skin disorders such as psoriasis, acne, and eczema. By participating, you contribute to medical research aimed at improving healthcare solutions. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence. 4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to: Age, gender, and health requirements specific to the trial. Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments. 5. Screening and Selection Applicants will undergo a thorough screening process that includes: Completion of detailed questionnaires. Submission of medical records and other requested documentation. Possible physical and diagnostic evaluations. Disclosure of all medications or treatments being used. Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk. 6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner. 7. Risks and Benefits Participants must understand the following: Risks: Use of Nygela may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process. Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders. 8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits. 9. Participant Responsibilities By participating in the Nygela clinical trials, you agree to: Follow all instructions provided by the research team. Report any side effects, adverse events, or concerns promptly. Attend all scheduled visits and comply with study protocols. Failure to meet these responsibilities may result in removal from the trial. 10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment. 11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if: You no longer meet the eligibility requirements. You fail to comply with study protocols. Continuation in the trial is deemed unsafe or inappropriate. 13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document. 14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law. 15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms. 16. International Participation Clinical trials for Nygela are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For questions, concerns, or further information, please contact us at: Email: info@ablatotech.com Acknowledgment and Agreement: By submitting an application for the Nygela clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.

Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. What's on your mind? Get in touch with Ablatotech. Reach out to us for inquiries about our groundbreaking innovations, clinical trials, or collaborations. We're here to help and answer your questions. Please reach out by using this form or email us - info@ablatotech.com info@ablatotech.com First Name Last Name Email Message Send Thanks for submitting!

Terms of Use for Participation in Tarysol Clinical Trials at Ablatotech Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Tarysol clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Tarysol Clinical Trials aim to evaluate the safety, efficacy, and potential applications of Tarysol, a natural compound designed to rapidly solubilize blood clots in veins. By participating, you contribute to medical research aimed at improving healthcare solutions. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence. 4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to: Age, gender, and health requirements specific to the trial. Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments. 5. Screening and Selection Applicants will undergo a thorough screening process that includes: Completion of detailed questionnaires. Submission of medical records and other requested documentation. Possible physical and diagnostic evaluations. Disclosure of all medications or treatments being used. Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk. 6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner. 7. Risks and Benefits Participants must understand the following: Risks: Use of Tarysol may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process. Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders. 8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits. 9. Participant Responsibilities By participating in the Tarysol clinical trials, you agree to: Follow all instructions provided by the research team. Report any side effects, adverse events, or concerns promptly. Attend all scheduled visits and comply with study protocols. Failure to meet these responsibilities may result in removal from the trial. 10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment. 11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if: You no longer meet the eligibility requirements. You fail to comply with study protocols. Continuation in the trial is deemed unsafe or inappropriate. 13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document. 14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law. 15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms. 16. International Participation Clinical trials for Tarysol are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For questions, concerns, or further information, please contact us at: Email: info@ablatotech.com Acknowledgment and Agreement: By submitting an application for the Tarysol clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.

Terms and Conditions for Participation in Liprovia Clinical Trials Effective Date: 02/12/2025 Last Updated: 3/14/2025 1. Acceptance of Terms By applying to participate in the Liprovia clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Submission of an application does not guarantee inclusion in the trial; final selection is determined after a detailed screening process. 2. Purpose of Clinical Trial The Liprovia clinical trial aims to evaluate the safety, effectiveness, and tolerability of Liprovia, an oral, natural GLP-1 agonist-like drug developed for weight loss. By participating, you are contributing to research that may advance medical solutions for weight management. 3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation at any time without penalties or consequences. 4. Eligibility Requirements To apply for the Liprovia clinical trials, you must meet the eligibility requirements established for the study, which include but are not limited to: Meeting specific age and health criteria outlined during the screening process. Absence of certain pre-existing medical conditions, which will be disclosed during initial assessments. 5. Screening and Selection Applicants will be required to complete a thorough screening process, including: Submission of medical history and relevant documentation. Completion of health-related questionnaires. Attendance at diagnostic evaluations, if required. Ablatotech reserves the right to decline applications from individuals who do not meet eligibility criteria or pose safety risks. 6. Privacy and Data Protection Your personal and medical data will be treated with strict confidentiality. Ablatotech adheres to data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Your information will be used solely for research purposes in a de-identified format. 7. Risks and Benefits Participants should be aware of the following: Risks: Use of Liprovia may involve potential side effects or adverse reactions. These will be detailed during the informed consent process. Benefits: While personal health benefits cannot be guaranteed, your participation contributes to research that may benefit others in the future. 8. Informed Consent Participants must review and sign an Informed Consent Form before being enrolled in the study. This document will outline in detail the purpose, procedures, potential risks, and benefits of the clinical trial. 9. Participant Responsibilities By enrolling in the Liprovia clinical trials, participants agree to: Comply with all study protocols, including medication guidelines and follow-up assessments. Attend all scheduled appointments and notify the research team of any side effects or adverse events. Provide accurate and truthful information throughout the trial period. 10. Compensation Participants may be eligible for compensation to cover time, travel, and related expenses. Details will be discussed and agreed upon before enrollment. 11. Medical Care and Support In case of harm or adverse effects directly resulting from participation in the clinical trial, Ablatotech will provide appropriate medical care as outlined in the Informed Consent Form. 12. Termination of Participation Ablatotech reserves the right to terminate a participant’s involvement in the trial if: Safety concerns arise. Study protocols are not followed. Continued participation becomes inappropriate for health reasons. 13. Intellectual Property All data, discoveries, and intellectual property resulting from the Liprovia clinical trial are the sole property of Ablatotech. Participants will not receive ownership rights or additional compensation beyond what is specified in the agreement. 14. Limitation of Liability Ablatotech is not responsible for any damages beyond those explicitly stated in the informed consent documentation, except as required by law. 15. Amendments to Terms These Terms of Use are subject to change. Participants will be notified of significant updates, and continued participation constitutes agreement to the revised terms. 16. International Participation Clinical trials for Liprovia are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants. 17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name. 18. Contact Information For inquiries or concerns regarding the Liprovia clinical trials, please contact: Email: info@ablatotech.com Acknowledgment and Agreement By submitting an application for the Liprovia clinical trials, you affirm that you have read, understood, and agreed to these Terms of Use.